<DOC>
	<DOCNO>NCT00997906</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , gemcitabine hydrochloride , carboplatin , paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy together radiation therapy kill tumor cell . It yet know whether give cisplatin together radiation therapy effective without gemcitabine hydrochloride , carboplatin , paclitaxel treat patient nasopharyngeal cancer . PURPOSE : This randomized phase II/III trial study well give cisplatin together radiation therapy work compare give cisplatin radiation therapy together gemcitabine hydrochloride , carboplatin , paclitaxel treat patient locally advanced nasopharyngeal cancer .</brief_summary>
	<brief_title>Cisplatin RT With Without Gemcitabine , Carboplatin , Paclitaxel Treating Patients With Locally Advanced NPC</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare 5-year overall survival patient locally advanced nasopharyngeal cancer treat concurrent cisplatin radiotherapy v without induction chemotherapy comprise gemcitabine hydrochloride , carboplatin , paclitaxel . Secondary - To assess compare disease-free survival , distant metastasis rate , toxicity , quality life patient treat regimen . OUTLINE : Patients stratify N-stage ( N0-1 v N2-3 ) randomize 1 2 treatment arm . - Arm I : Patients receive cisplatin IV 2 hour weekly week 1-8 undergo intensity-modulated radiotherapy daily , 5 day week , week 1-7 ( 6½ week total 33 fraction ) . - Arm II : Patients receive induction chemotherapy comprise gemcitabine hydrochloride IV 30 minute , carboplatin IV 1 hour , paclitaxel IV 1 hour day 1 8 . Treatment repeat every 21 day 3 course . Beginning least 3 week last dose induction chemotherapy , patient receive cisplatin undergo radiotherapy arm I . Quality life assess periodically . After completion study treatment , patient follow every 2 month 1 year , every 4 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : Patients eligible inclusion follow criterion fulfil : 1 . Have give write informed consent , understanding consent may withdraw time without prejudice . 2 . Locoregional advance NPC UICC ( 1997 ) Stages T3 4 N , Stage T , N2 3 . 3 . A histological diagnosis WHO Type II III NPC must establish time investigator must review confirm diagnosis prior randomization . 4 . No evidence distant metastasis stag work ( include lung , liver bone image ) . 5 . Cross sectional imaging primary neck disease ( MRI prefer ) 6 . Evaluable disease must present . 7 . Performance status ECOG grade 0 1 ( see Appendix I ) . 8 . No prior tumour therapy 9 . Adequate bone marrow , renal hepatic function : Bone marrow : WBC &gt; 3000 / mm3 ( ANC &gt; 1500 / mm3 ) , Platelets &gt; 100 000 / mm3 , Hb &gt; 10 gm/dl Renal : serum creatinine within institutional normal range ( ) low low limit institutional normal range calculate creatinine clearance &gt; 50 ml / min Hepatic : enzyme ( SAP , SGOT ) &lt; 2x normal bilirubin &lt; 24 µmol / l. 10 . At least 18 year age , either sex . Exclusion criterion : Patients exclude study follow criterion fulfil : 1 . Uncontrolled hypercalcaemia : calcium ≥ 2.7 mmol/L ( 10.8 mg/dL ) . 2 . Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) . 3 . Other serious concomitant systemic disorder incompatible study ( discretion investigator ) . 4 . Have serious active infection . 5 . Hepatitis B carrier 6 . Prior treatment include chemotherapy radiotherapy . 7 . Pregnant lactate female subject subject reproductive potential implementing adequate contraceptive measure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
</DOC>